Merck (MRK.N) rose by over 1%. Merck and HANSOH PHARMA have reached a global exclusive licensing agreement for the oral GLP-1 receptor agonist currently under development.
- Latest
- Detail
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
00:59
Bernstein has raised Amazon's Target Price from $235.00 to $265.00.
AMZN-0.43%
00:57
Merck invested as much as 2 billion dollars to acquire the global rights to a weight loss drug under development by HANSOH PHARMA.
HANSOH PHARMA+3.94%
00:55
Israeli Prime Minister visits the summit of Mount Hermon, stating that the Israeli military will remain in the Golan Heights buffer zone.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.